ASCO® 2020

Enfortumab Vedotin | Urothelial Carcinoma | Abstract 5044

Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma

Enfortumab Vedotin | Urothelial Carcinoma | Abstract TPS5092

Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab for locally advanced or metastatic urothelial carcinoma

Enfortumab Vedotin | Urothelial Carcinoma | Abstract TPS3647

EV-202: A Phase 2 Study of Enfortumab Vedotin in Patients With Select Previously Treated Locally Advanced or Metastatic Solid Tumors